| Assessment Status | Rapid Review Complete |
| HTA ID | 20040 |
| Drug | Imipenem/cilastatin/relebactam |
| Brand | Recarbrio® |
| Indication | For the treatment of infections due to aerobic gram-negative organisms in adults with limited treatment options. |
| Assessment Process | |
| Rapid review commissioned | 31/08/2020 |
| Rapid review completed | 21/10/2020 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of imipenem/cilastatin/relebactam compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
